Three-step pretargeting methods and compounds

Details Three-step pretargeting methods and compounds Three-step pretargeting methods and compounds

1999-05-21

2002-03-19

Ceperley, Mary E. (Department: 1641)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

Attached to antibody or antibody fragment or immunoglobulin;...

C424S001490, C424S009360, C424S009363, C424S174100, C424S178100

Reexamination Certificate

active

06358490

ABSTRACT:

TECHNICAL FIELD
The present invention relates to methods, compounds, compositions and kits useful for delivering to a target site a targeting moiety that is conjugated to one member of a ligand/anti-ligand pair. After localization and clearance of the targeting moiety conjugate, direct or indirect binding of a diagnostic or therapeutic agent conjugate at the target site occurs. Methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as the related compounds, are also disclosed.
SUMMARY OF THE INVENTION
The present invention describes three-step pretargeting diagnostic and therapeutic methods. Three-step pretargeting protocols feature administration of a targeting moiety-ligand conjugate, which is allowed to localize at a target site and to dilute in the circulation. Subsequently administered anti-ligand binds to the targeting moiety-ligand conjugate in both blood and at a target site and clears unbound antibody-ligand conjugate from the blood. A diagnostic or therapeutic agent-ligand conjugate that exhibits rapid whole body clearance is then administered and binds to the targeting moiety-ligand-anti-ligand localized at a target site, thereby constituting the third target site-localized component in the protocol.
Preferred three-step pretargeting methods of the present invention employ biotin/avidin as the ligand/anti-ligand binding pair. These preferred three-step pretargeting methods involve the administration of biotin conjugated to therapeutic or diagnostic radionuclides or other active agents such as chemotherapeutic drugs, anti-tumor agents such as cytokines and the like. Y-90-DOTA-biotin conjugates are particularly preferred in the practice of the present invention.


REFERENCES:
patent: 4639365 (1987-01-01), Shrry
patent: 4647447 (1987-03-01), Gries et al.
patent: 4678667 (1987-07-01), Meares et al.
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 4923985 (1990-05-01), Gansow et al.
patent: 5141966 (1992-08-01), Porath
patent: 5246692 (1993-09-01), Gansow et al.
patent: 5256395 (1993-10-01), Barbet et al.
patent: 5326778 (1994-07-01), Rosebrough
patent: 5578287 (1996-11-01), Theodore et al.
patent: 5608060 (1997-03-01), Axworthy et al.
patent: 5630996 (1997-05-01), Reno et al.
patent: 6022966 (2000-02-01), Gustavson et al.
patent: 327 365 (1989-08-01), None
patent: 451 824 (1991-10-01), None
patent: 496 074 (1992-07-01), None
patent: Pct/EP90/00565 (1990-10-01), None
patent: WO 92/12730 (1992-08-01), None
patent: WO 93/15210 (1993-08-01), None
patent: WO 93/25240 (1993-12-01), None
Kricka et al., “Survey of Methods of Measuring Human Anti-Mouse Antibodies,” HAMA Survey Group,Clinica Chimica Acta. 215: 153-163, 1993.
Jokiranta et al., “Biotinylation of Monoclonal Antibodies Prevents Their Ability to Activate the Classical Pathway of Complement,”The Journal of Immunology 151(4): 1'14-2131, 1993.
Chatterjee,Cancer Immunol. Immunopathol 38: 75-82, 1994.
Osband et al.,Immunol. Today 11(6): 193-195, 1990.
Curti,Crit. Rev. Oncol./Hematol. 14: 29-39, 1993.
Jain,Scientific American 271(1): 58-65, 1994.
Zwierzina,Stem Cells 11: 144-153, 1993.
Rosebrough, “Plasma Stability and Pharmacokinetics of Radio-labeled Deferoxamine-Biotin Derivatives,”J. Nucl. Med.: p. 880, Abstract No. 235, 1992.
Paganelli et al., “Monoclonal antibody pretargetting techniques for tumour localization: the aviding-biotin system,”Nuclear Medicine Communications 12: 211-234, 1991.
Wolf et al.,Methy. Enzym. 184: 103, 1990.
Harris et al.,Tibtech 11: 42, 1993.
Dermer,Biotechnology 12: 320, 1994.
Bloom, “The Power of Negative Thinking,”J. Clin. Invest. 91: 1265-1266, 1993.
Moore, “The Future of Cytokine Combination Therapy,”Cancer 67: 2718-2726, 1991.
Sheldon et al., “Targeting of [111In]Biocytin to Cultured Ovarian Adenocarcinoma Cells Using covalent Monoclonal Antibody-Streptavidin Conjugates,”Appl. Radiat. Isot.43(11): 1399-1402, 1992.
Goodwin, “New Methods for Localizing Infection: A role for Avidin-Biotin,?”J. Nucl. Med. 33(10): 1816-1818, 1992.
Goodwin et al., “Pretargeted Immunoscintography: Effect of Hapten Valency on Murine Tumor Uptake,”J. Nucl. Med. 33(11): 2006-2013, 1992.
McMurry et al., “Covenient Synthesis of Bifunctional Tetraaza Macrocycles,”Bioconjugate Chem. 3(2): 108-117, 1992.
Renn and Meares, “Large-Scale Synthesis of Bifunctional Chelating Agent 2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic Acid, and the Determination of Its Enantiomeric Purity by Chiral Chromatography,”Bioconjugate Chem. 3(6): 563-569, 1992.
Koch and Macke, “99mTc Labeled biotin conjugates in a Tumor “Pretargeting” Approach with Monoclonal Antibodies,”Angew. Chem. Intl. Ed. Engl. 31(11): 1507-1509, 1992.
Wu et al., “Investigations of N-Linked Macrocycles for111In and90Y Labeling of Proteins,”NoNucl. Med. Biol. Int. J. Radiat. Appl. Instrum. Part B 19(2): 239-244, 1992.
Goodwin et al., “Pharmacokinetics of Biotin-Chelate Conjugates for Pretargeted Avidin-biotin Immunoscintigraphy,”J. Nucl. Med.: p. 880, Abstract No. 232, 1992.
Dischino et al., “Synthesis of Nonionic Gadolinium Chelates Useful as Contrast Agents for Magnetic Resonance Imaging,”Inorg. Chem. 30: 1265-1269, 1992.
Sieving et al., “Preparation and Characterization of Paramagnetic Polychelates and Their Protein Conjugates,”Bioconjugate Chem. 1: 65-71, 1990.
Parker et al., “Implementation of macrocycle conjugated antibodies for tumour-targeting,”Pure&Appl. Chem. 61(9): 1637-1641, 1989.
Riesen et al., “Synthesis and X-Ray Structural Characterisation of Seven Co-ordinate Macrocyclic In3+Complexes with Relevance to Radiopharmaceutical Applications,”J. Chem. Soc., Chem Commun.: 460-462, 1989.
Moi and Meares, “The Peptide Way to Macrocyclic Bifunctional Chelating Agents: Synthesis of 2-(p-Nitorbenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″, N′″-tetraacetic Acid and Study of Its Yttrium(III) Complex,”J. Am. Chem. Soc. 110: 6267-6269, 1988.
Kasprzyk and Wilkins, “Kinetics of Interaction of Metal Ions with Two Tetraaza Tetraacetate Macrocycles,”Inorg. Chem. 21: 3349-3352, 1982.
International Search Report for PCT Patent Application No. PCT/US/05406.
Green, “1. The Use of [14C]Biotin For Kinetic Studies And For Assay,”Biochem. J. 89: 585-590, 1963.
Kalofonos et al., “Imaging of Tumor in Patients with Indium-111-Labeled Biotin and Streptavidin-Conjugated Antibodies: Preliminary Communication,”J. Nucl. Med. 31(11): 1791-1796, 1990.
Hnatowich et al., “Investigations of Avidin and Biotin for Imaging Applications,”J. Nucl. Med. 28: 1294-1302, 1987.
Paganelli et al., “Intraperitoneal Radio-Localization Of Tumors Pre-Targeted By Biotinylated Monoclonal Antibodies,”Int. J. Cancer 45: 1184-1189, 1990.
Goodwin/Hnatowich,J. Nucl. Med. 32(4): 750-751, 1991, Letter to the Editor/Reply.
Virzi et al., “The Preparation And Evaluation Of 12 Biotin Derivatives Labeled With Tc-99M,”J. Nucl. Med.: p. 920, Abstract No. 403, 1992.
Rosario et al., “Bolton-Hunter And Biotin Derivatized Polylysine: A New Multi-Valent Peptide Reagent For In-Vivo Pre-Targeting With Streptavidin Conjugates,”J. Nucl. Med. 32(5): p. 993, Abstract No. 356, 1991.
Axworthy et al, “Antibody Pretargeting For Radioimmunotherapy: A Three-Step Approach In Tumored Nude Mice,”The Journal of Nuclear Medicine; Proceedings Of The 39thAnnual Meeting 33: p. 880, Abstract No. 234, 1992.
Galli et al., “A Radiopharmaceutical For The Study Of The Liver:99mTc-DTPA-ASIALO-OROSOMUCOID. II: Human Dynamic and Imaging Studies,”The Journal of Nuclear Medicine and Allied Sciences 32(2): 117-126, 1988.

Affiliated with

Also associated with

Rating

Three-step pretargeting methods and compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Three-step pretargeting methods and compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Three-step pretargeting methods and compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2883208